Kaleido Anticipated Potential Conflict With US FDA Over Its Microbiome Therapy Product
Warning letter from agency for conducting clinical studies in COVID-19 patients without filing IND follows Kaleido decision the product could be designated as a food and thereby bypass an investigational new drug application.
You may also be interested in...
Director of the US FDA’s Office of New Drugs says there will be a greater focus on identifying the optimal dose before a drug candidate advances into Phase III trials, but the problem is not limited to oncology, the target of Project Optimus.
Peter Stein says FDA will set criteria for holding a virtual meeting and will be seeking stakeholder feedback.
Head of Office of New Drugs highlights programs being established under PDUFA VII that could help overcome obstacles in drug development.